Southpoint Capital Advisors LP Fennec Pharmaceuticals Inc. Transaction History
Southpoint Capital Advisors LP
- $3.62 Billion
- Q4 2024
A detailed history of Southpoint Capital Advisors LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Southpoint Capital Advisors LP holds 4,077,214 shares of FENC stock, worth $27.2 Million. This represents 0.71% of its overall portfolio holdings.
Number of Shares
4,077,214
Previous 4,077,214
-0.0%
Holding current value
$27.2 Million
Previous $20.4 Million
26.4%
% of portfolio
0.71%
Previous 0.57%
Shares
2 transactions
Others Institutions Holding FENC
# of Institutions
64Shares Held
14.7MCall Options Held
10KPut Options Held
83.8K-
Sonic Gp LLC Honolulu, HI2.41MShares$16 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$15 Million11.1% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$7.91 Million0.0% of portfolio
-
Dg Capital Management, LLC New York, NY1.11MShares$7.42 Million2.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA970KShares$6.46 Million0.0% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $174M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...